9-Jan-2026 7:05 AM CST - Business Wire Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025. Preliminary Fourth Quarter and Full-Year 2025 Financial Results (unaudited) Total fourth quarter and full year revenue expected to be approximately $20.7 million and
4-Nov-2025 7:00 AM CST - Business Wire Delcath Systems Reports Third Quarter 2025 Results and Business Highlights Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Total revenue of $20.6 million, compared with $11.2 million in the third quarter of 2024 HEPZATO KIT revenue of $19.3 million, compared to $10.0 million
21-Oct-2025 7:30 AM CST - Business Wire Delcath Systems to Host Third Quarter 2025 Earnings Call Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 4, 2025, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Tuesday, November
6-Aug-2025 7:00 AM CST - Business Wire Delcath Systems Reports Second Quarter 2025 Results and Business Highlights Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Total revenue of $24.2 million, compared with $7.8 million in the second quarter of 2024 HEPZATO KIT revenue of $22.5 million, compared to $6.6 million in
23-Jul-2025 3:01 PM CST - Business Wire Delcath Systems to Host Second Quarter 2025 Earnings Call Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2025, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Wednesday, August 6, 20
8-May-2025 6:30 AM CST - Business Wire Delcath Systems Reports First Quarter 2025 Results and Business Highlights Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT revenue of $18.0 million, compared to $2.0 million in th
24-Apr-2025 3:01 PM CST - Business Wire Delcath Systems to Host First Quarter 2025 Earnings Call Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 8, 2025, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 8, 2025 Time
24-Mar-2025 3:01 PM CST - Business Wire Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in the CG Horizons in Oncology Virtual Conference on April 7, 2025 at 10:00 a.m. ET. Investors interested in participating should contact their Canaccord representative. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional on
6-Mar-2025 7:00 AM CST - Business Wire Delcath Systems Reports Fourth Quarter and Full Year 2024 Results Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024. Fourth Quarter and Full Year 2024 Financial Results Total fourth quarter and full year revenue of $15.1 million and $37.2 million, respectively HEPZATO KIT fourth quarte
9-Jan-2026 7:05 AM CST - Business Wire Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025. Preliminary Fourth Quarter and Full-Year 2025 Financial Results (unaudited) Total fourth quarter and full year revenue expected to be approximately $20.7 million and
4-Nov-2025 7:00 AM CST - Business Wire Delcath Systems Reports Third Quarter 2025 Results and Business Highlights Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Total revenue of $20.6 million, compared with $11.2 million in the third quarter of 2024 HEPZATO KIT revenue of $19.3 million, compared to $10.0 million
21-Oct-2025 7:30 AM CST - Business Wire Delcath Systems to Host Third Quarter 2025 Earnings Call Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 4, 2025, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Tuesday, November
6-Aug-2025 7:00 AM CST - Business Wire Delcath Systems Reports Second Quarter 2025 Results and Business Highlights Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Total revenue of $24.2 million, compared with $7.8 million in the second quarter of 2024 HEPZATO KIT revenue of $22.5 million, compared to $6.6 million in
23-Jul-2025 3:01 PM CST - Business Wire Delcath Systems to Host Second Quarter 2025 Earnings Call Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2025, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Wednesday, August 6, 20
8-May-2025 6:30 AM CST - Business Wire Delcath Systems Reports First Quarter 2025 Results and Business Highlights Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT revenue of $18.0 million, compared to $2.0 million in th
24-Apr-2025 3:01 PM CST - Business Wire Delcath Systems to Host First Quarter 2025 Earnings Call Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 8, 2025, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 8, 2025 Time
24-Mar-2025 3:01 PM CST - Business Wire Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in the CG Horizons in Oncology Virtual Conference on April 7, 2025 at 10:00 a.m. ET. Investors interested in participating should contact their Canaccord representative. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional on
6-Mar-2025 7:00 AM CST - Business Wire Delcath Systems Reports Fourth Quarter and Full Year 2024 Results Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024. Fourth Quarter and Full Year 2024 Financial Results Total fourth quarter and full year revenue of $15.1 million and $37.2 million, respectively HEPZATO KIT fourth quarte
